Finkelstein Thompson LLP Announces Investigation of ATS Medical, Inc.
April 29 2010 - 5:03PM
Business Wire
Finkelstein Thompson LLP is investigating potential claims on
behalf of shareholders of ATS Medical, Inc. (“ATS Medical” or the
“Company”) (Nasdaq: ATSI) arising from the Company’s announcement
of its intent to be acquired by Medtronic Inc. (“Medtronic”). Under
the terms of the agreement, ATS Medical shareholders will receive
$4.00 in cash for every share of ATS Medical stock they own in a
transaction valued at approximately $370 million.
The investigation is focused on potential insider interest in
the transaction, as well as the potential unfairness of the
consideration to ATS Medical’s shareholders and the process by
which ATS Medical’s Board of Directors considered and approved the
transaction. Indeed, at least one analyst set a price target for
$5.00 per share, and the merger agreement contains provisions
intended to deter competing bids.
If you are interested in discussing your rights as an ATS
Medical shareholder, or have information relating to this
investigation, please contact Finkelstein Thompson's Washington, DC
offices at (877) 337-1050 or by email at contact@finkelsteinthompson.com.
Finkelstein Thompson LLP has spent over three decades delivering
outstanding representation to institutional and individual clients
in financial litigation, and has been appointed as lead or co-lead
counsel in dozens of shareholder class actions. Indeed, the firm
has served in leadership roles in cases that have recovered over $1
billion for investors and consumers.
To learn more about Finkelstein Thompson LLP, please visit our
web site at www.finkelsteinthompson.com. Attorney
advertising. Prior results do not guarantee similar outcomes.
Ats Medical (MM) (NASDAQ:ATSI)
Historical Stock Chart
From Jul 2024 to Aug 2024
Ats Medical (MM) (NASDAQ:ATSI)
Historical Stock Chart
From Aug 2023 to Aug 2024
Real-Time news about Ats Medical (MM) (NASDAQ): 0 recent articles
More Finkelstein Thompson LLP News Articles